title: QT dispersion correlates with systolic rather than diastolic parameters in patients receiving anthracycline treatment.
abstract: OBJECTIVE
  The aim of this study was to investigate the relation of QT dispersion to left ventricular (LV) systolic and diastolic function in patients undergoing anthracycline therapy.
  
  
  METHODS
  We used echocardiography to evaluate LV systolic and diastolic function and electrocardiography to evaluate QT dispersion and corrected QT dispersion (QTcD) in patients with hematological diseases, who received anthracycline therapy.
  
  
  METHODS
  Seventy-two patients with hematological diseases who were receiving anthracycline treatment were enrolled in the present study.
  
  
  RESULTS
  LV end-diastolic diameter or LV end-systolic diameter had a significant positive correlation to QTcD (r = 0.35, p < 0.01, r = 0.43, p < 0.01). Also left ventricular ejection fraction of (LVEF) or fractional shortening had a significant negative correlation to QTcD (r = -0.46, p < 0.001, r = -0.27, p = 0.02). The highest QTcD group had a significantly larger LV end-diastolic diameter or LV end-systolic diameter than the lowest QTcD [48.5 +/- 5.7 vs. 44.4 +/- 4.5 (mm), p < 0.001, 34.1 +/- 6.4 vs. 28.8 +/- 4.3 (mm), p < 0.001] and the highest QTcD group had a significantly lower LVEF than the lowest QTcD [57.5 +/- 8.0 vs. 65.5 +/- 6.4 (%), p < 0.001]. On the other hand, none of the diastolic function markers were significantly correlated with QTcD.
  
  
  CONCLUSIONS
  We concluded that increased QTcD is correlated with LV dilation and systolic dysfunction induced by anthracycline therapy, and does not reflect a dispersion of ventricular repolarization or asynchronous motion.
authors.affiliation: Clinical Hematology and Clinical Diagnostics. Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585.
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Nakamae
authors.forename: Kei
authors.initials: K
authors.lastname: Tsumura
authors.forename: Mika
authors.initials: M
authors.lastname: Akahori
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Terada
authors.forename: Takahisa
authors.initials: T
authors.lastname: Yamane
authors.forename: Takeo
authors.initials: T
authors.lastname: Hayashi
authors.forename: Ikuko
authors.initials: I
authors.lastname: Saito
authors.forename: Mutsuo
authors.initials: M
authors.lastname: Kaneko
authors.forename: Noboru
authors.initials: N
authors.lastname: Okamoto
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Ichihara
authors.forename: Kensuke
authors.initials: K
authors.lastname: Ohta
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hino
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D018943:Anthracyclines / Q000009:adverse effects* / Q000627:therapeutic use; D001331:Automation; D016022:Case-Control Studies; D003971:Diastole / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D015150:Echocardiography, Doppler; D004562:Electrocardiography; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006334:Heart Function Tests; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011336:Probability; D012016:Reference Values; D012680:Sensitivity and Specificity; D013599:Systole / Q000187:drug effects
chemical_list: D018943:Anthracyclines